Clinical Experience with α-Particle–Emitting (211)At: Treatment of Recurrent Brain Tumor Patients with (211)At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

α-Particle–emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of α-parti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Zalutsky, Michael R., Reardon, David A., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Friedman, Henry S., McLendon, Roger E., Wong, Terence Z., Bigner, Darell D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2007
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832604/
https://ncbi.nlm.nih.gov/pubmed/18077533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.046938
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi